Floatz logo

Omalizumab

Allergic Asthma

Qianfoshan Hospitalmonoclonal_antibodyPhase 4 / ApprovedActive
BBB
76/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Allergic Asthma cohort.

Asset / SponsorPhaseRating
5-hydroxytryptophan
Indiana University
Phase 2CCC
LIGELIZUMAB
Novartis Pharmaceuticals
Phase 1/2CCC
Gamma Tocopherol
University of North Carolina, Chapel Hill
Phase 1/2NR

Same molecule, other indications

Omalizumab is also rated in:

asthmaDormant
BB
Indicative ·
68 / 100
View asset →
chronic rhinosinusitisDormant
BB
Indicative ·
65 / 100
View asset →
allergic bronchopulmonary aspergillosisDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →